INTRAVENTRICULAR GENTAMICIN THERAPY IN GRAM-NEGATIVE BACILLARY MENINGITIS OF INFANCY

of the Second Neonatal Meningitis Cooperative Study Group Report of the Second Neonatal Meningitis Cooperative Study Group, GeorgeH Mccracken, SusanG Mize, Norma Threlkeld

Research output: Contribution to journalArticle

203 Scopus citations

Abstract

In a multicentre controlled trial in the U.S.A. and Latin America 52 infants with meningitis and ventriculitis were randomly assigned to receive either systemic ampicillin and gentamicin or intraventricular gentamicin plus systemic antimicrobial agents. The ætiological agents most often encountered were Escherichia coli in the U.S. infants and Salmonella spp. in Latin American infants. Infants receiving systemic antibiotics plus intraventricular gentamicin had a significantly higher mortality rate (42·9%) than those who received systemic therapy only (12·5%). Duration of positive CSF cultures and morbidity rates were not significantly different in the two treatment groups. The concentrations of gentamicin in ventricular and lumbar CSF 1-6 h after an intraventricular dose of 2·5 mg gentamicin were 10-130 μg/ml and 8-85 μg/ml, respectively. The study was terminated early because of the higher mortality rate in the intraventricular-therapy group. Intraventricular gentamicin should not be used as routine treatment for neonatal meningitis caused by gram-negative enteric bacilli.

Original languageEnglish (US)
Pages (from-to)787-791
Number of pages5
JournalThe Lancet
Volume315
Issue number8172
DOIs
StatePublished - Apr 12 1980

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'INTRAVENTRICULAR GENTAMICIN THERAPY IN GRAM-NEGATIVE BACILLARY MENINGITIS OF INFANCY'. Together they form a unique fingerprint.

  • Cite this

    Report of the Second Neonatal Meningitis Cooperative Study Group, O. T. S. N. M. C. S. G., Mccracken, G., Mize, S., & Threlkeld, N. (1980). INTRAVENTRICULAR GENTAMICIN THERAPY IN GRAM-NEGATIVE BACILLARY MENINGITIS OF INFANCY. The Lancet, 315(8172), 787-791. https://doi.org/10.1016/S0140-6736(80)91291-X